Sutro Biopharma (NASDAQ:STRO) PT Lowered to $8.00

Sutro Biopharma (NASDAQ:STRO) had its price objective dropped by stock analysts at Wedbush from $12.00 to $8.00 in a research report issued on Tuesday, MarketBeat Ratings reports. The brokerage currently has an “outperform” rating on the stock. Wedbush’s price objective indicates a potential upside of 62.27% from the stock’s current price. Wedbush also issued estimates for Sutro Biopharma’s Q1 2025 earnings at ($0.83) EPS, Q2 2025 earnings at ($0.88) EPS, Q3 2025 earnings at ($0.74) EPS and Q4 2025 earnings at ($0.76) EPS.

A number of other research analysts have also weighed in on STRO. JMP Securities reissued a “market outperform” rating and set a $17.00 target price on shares of Sutro Biopharma in a report on Tuesday. HC Wainwright decreased their price objective on shares of Sutro Biopharma from $16.00 to $12.00 and set a “buy” rating on the stock in a report on Tuesday. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $13.71.

Sutro Biopharma Stock Performance

Sutro Biopharma stock opened at $4.93 on Tuesday. The stock has a 50-day simple moving average of $4.47 and a 200 day simple moving average of $3.77. The stock has a market capitalization of $300.48 million, a P/E ratio of -2.77 and a beta of 0.95. Sutro Biopharma has a 52 week low of $2.01 and a 52 week high of $6.11.

Insider Buying and Selling

In related news, insider Nicki Vasquez sold 12,185 shares of the stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $5.00, for a total transaction of $60,925.00. Following the sale, the insider now owns 12,803 shares in the company, valued at approximately $64,015. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 6.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Sutro Biopharma

A number of institutional investors have recently modified their holdings of STRO. Nisa Investment Advisors LLC boosted its holdings in shares of Sutro Biopharma by 14,125.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 8,820 shares of the company’s stock valued at $38,000 after acquiring an additional 8,758 shares in the last quarter. Wells Fargo & Company MN grew its holdings in shares of Sutro Biopharma by 331.7% during the fourth quarter. Wells Fargo & Company MN now owns 5,690 shares of the company’s stock worth $46,000 after purchasing an additional 4,372 shares during the last quarter. Point72 Hong Kong Ltd acquired a new position in shares of Sutro Biopharma in the second quarter valued at approximately $46,000. Tower Research Capital LLC TRC raised its holdings in Sutro Biopharma by 342.3% in the 3rd quarter. Tower Research Capital LLC TRC now owns 15,128 shares of the company’s stock valued at $52,000 after buying an additional 11,708 shares during the last quarter. Finally, Ergoteles LLC bought a new position in Sutro Biopharma in the 2nd quarter valued at approximately $54,000. Institutional investors and hedge funds own 96.99% of the company’s stock.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. It develops site-specific and novel-format antibody drug conjugates (ADC) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. The company's product candidates include STRO-001, an ADC directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials.